Incyte | INCY - Assets



Incyte reported $5.82B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Exelixis USD 2.68B 159.17M Jul/2025
Gilead Sciences USD 55.72B 713M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
MacroGenics USD 245.42M 16.24M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Novartis USD 104.4B 2.15B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
PTC Therapeutics USD 2.63B 21.23M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025